scholarly journals Clinical and Molecular Features of Patients with Gliomas Harboring IDH1 Non-canonical Mutations: A Systematic Review and Meta-Analysis

Author(s):  
Vincenzo Di Nunno ◽  
Enrico Franceschi ◽  
Alicia Tosoni ◽  
Lidia Gatto ◽  
Ilaria Maggio ◽  
...  
2013 ◽  
Vol 108 (7) ◽  
pp. 1042-1056 ◽  
Author(s):  
Quirinus J M Voorham ◽  
Eveline J A Rondagh ◽  
Dirk L Knol ◽  
Manon van Engeland ◽  
Beatriz Carvalho ◽  
...  

2020 ◽  
Vol 183 (3) ◽  
pp. 503-514
Author(s):  
Angus J. Lloyd ◽  
Éanna J. Ryan ◽  
Michael R. Boland ◽  
Sami Abd Elwahab ◽  
Carmel Malone ◽  
...  

2021 ◽  
Author(s):  
Vincenzo Di Nunno ◽  
Enrico Franceschi ◽  
Alicia Tosoni ◽  
Lidia Gatto ◽  
Ilaria Maggio ◽  
...  

Abstract Purpose The canonical isocitrate dehydrogenase 1 R132 mutation (IDH1 R132) is the most frequent mutation among IDH mutated gliomas. Non-canonical IDH1 mutations or IDH2 mutations are unusual and their clinical and biological role is still unclear.Methods We performed a systematic review and meta-analysis aimed to assess the clinical role of IDH non-canonical mutations. ResultsOverall, we selected 13 of 3513 studies reporting data of 4007 patients with a diagnosis of grade 2 and grade 3 including 3091 patients with a molecularly proven IDH1 or IDH2 mutation. Patients with non-canonical IDH1 mutations were younger and presented a higher DNA methylation level as compared to those with canonical IDH1 R132H alteration. The overall incidence of non-canonical IDH1 mutations was 7.9% (95% CI 5.4 – 10.7%) in patients with IDH mutated gliomas. There was no statistical difference in terms of incidence between patients with grade 2 or grade 3 glioma. Patients with non-canonical IDH mutations had a lower rate of 1p19q codeletion (risk difference: 31%, 95% CI 23 -38%) and presented a significantly prolonged survival (pooled-HR 0.47, 95% CI, 0.28-0.81) as compared to those with IDH1 R132H mutation. Conclusion Non-canonical IDH1 mutations occur in 7.9% of IDH mutated gliomas and recognize a specific subgroup of patients with an improved survival despite a lower rate of 1p19q codeletion. Data about the type of IDH mutation should be collected in clinical practice and within interventional trials as this could be a critical variable for an improved patient’s stratification and selection.


Author(s):  
Jacqueline P Whitehouse ◽  
Meegan Howlett ◽  
Aniello Federico ◽  
Marcel Kool ◽  
Raelene Endersby ◽  
...  

Abstract Background Cranial radiation therapy is essential in treating many pediatric cancers, especially brain tumors, however its use comes with the risk of developing second malignancies. Cranial radiation-induced gliomas (RIGs) are aggressive high-grade tumors with a dismal prognosis, for which no standard therapy exists. A definitive molecular signature for RIGs has not yet been established. We sought to address this gap by performing a systematic review and meta-analysis of the molecular features of cranial RIGs. Methods A systematic review of the literature was performed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. English language articles and case reports referring to radiation-induced high-grade gliomas located in the human brain that included molecular analyses were identified, evaluated and data extracted for collation. Results Of 1727 records identified, 31 were eligible, containing 102 unique RIGs with molecular data. The most frequent genetic alterations in RIGs included PDGFRA or TP53 mutations, PDGFRA or CDK4 amplifications, and CDKN2A deletion, along with 1q gain, 1p loss and 13q loss. Of note, mutations in ACVR1, EGFR, H3F3A, HIST1H3B, HIST1H3C, IDH2, SMARCB1 or the TERT promoter were not observed. A comparative analysis revealed that RIGs are molecularly distinct from most other astrocytomas and gliomas and instead align most closely with the pedGBM_RTK1 subgroup of pediatric glioblastoma. Conclusions This comprehensive analysis highlights the major molecular features of RIGs, demonstrates their molecular distinction from many other astrocytomas and gliomas, and reveals potential genetic drivers and therapeutic targets for this currently fatal disease.


2021 ◽  
Author(s):  
Yali Wei ◽  
Yan Meng ◽  
Na Li ◽  
Qian Wang ◽  
Liyong Chen

The purpose of the systematic review and meta-analysis was to determine if low-ratio n-6/n-3 long-chain polyunsaturated fatty acid (PUFA) supplementation affects serum inflammation markers based on current studies.


Sign in / Sign up

Export Citation Format

Share Document